AIM:MTPH

Stock Analysis Report

Executive Summary

Midatech Pharma plc, a biotechnology company, focuses on the research and development of oncology and rare disease products in the United Kingdom.

Snowflake

Fundamentals

Adequate balance sheet with questionable track record.


Similar Companies

Share Price & News

How has Midatech Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MTPH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-9.9%

MTPH

3.0%

GB Biotechs

0.5%

GB Market


1 Year Return

-72.5%

MTPH

0.5%

GB Biotechs

2.8%

GB Market

Return vs Industry: MTPH underperformed the UK Biotechs industry which returned 0.5% over the past year.

Return vs Market: MTPH underperformed the UK Market which returned 2.8% over the past year.


Shareholder returns

MTPHIndustryMarket
7 Day-9.9%3.0%0.5%
30 Day-39.2%7.4%1.7%
90 Day-36.0%4.7%3.7%
1 Year-72.5%-72.5%1.4%0.5%8.2%2.8%
3 Year-96.9%-96.9%4.3%2.3%24.3%8.5%
5 Yearn/a44.0%40.3%35.1%4.3%

Price Volatility Vs. Market

How volatile is Midatech Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Midatech Pharma undervalued compared to its fair value and its price relative to the market?

0.6x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MTPH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MTPH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MTPH is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MTPH is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MTPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MTPH is good value based on its PB Ratio (0.6x) compared to the GB Biotechs industry average (2.1x).


Next Steps

Future Growth

How is Midatech Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-16.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MTPH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MTPH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MTPH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MTPH's revenue (84.8% per year) is forecast to grow faster than the UK market (3.8% per year).

High Growth Revenue: MTPH's revenue (84.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MTPH's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Midatech Pharma performed over the past 5 years?

-4.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MTPH has high quality earnings.

Growing Profit Margin: MTPH's current net profit margins (-497.9%) are higher than last year (-1060%).


Past Earnings Growth Analysis

Earnings Trend: MTPH is unprofitable, and losses have increased over the past 5 years at a rate of -4% per year.

Accelerating Growth: Unable to compare MTPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MTPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: MTPH has a negative Return on Equity (-37.04%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Midatech Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: MTPH's short term assets (£14.3M) exceeds its short term liabilities (£3.4M)

Long Term Liabilities: MTPH's short term assets (14.3M) exceeds its long term liabilities (383.0K)


Debt to Equity History and Analysis

Debt Level: MTPH's debt to equity ratio (3.4%) is considered satisfactory

Reducing Debt: MTPH had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: MTPH has a low level of unsold assets or inventory.

Debt Coverage by Assets: MTPH's debt is covered by short term assets (assets are 17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MTPH has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MTPH has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.3% each year.


Next Steps

Dividend

What is Midatech Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.9%markettop25%5.3%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate MTPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MTPH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MTPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MTPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MTPH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of Midatech Pharma's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Craig Cook (52yo)

1.4yrs

Tenure

UK£158,772

Compensation

Dr. Craig Richard Cook, MBBCH, BSc (Hons), DA, MD, MBA has been Chief Executive Officer and Director of Midatech Pharma Plc since June 1, 2018 and served as its Chief Operating Officer since January 1, 201 ...


CEO Compensation Analysis

Compensation vs Market: Craig's total compensation ($USD203.02K) is below average for companies of similar size in the UK market ($USD319.03K).

Compensation vs Earnings: Insufficient data to compare Craig's compensation with company performance.


Management Age and Tenure

1.5yrs

Average Tenure

54yo

Average Age

Experienced Management: MTPH's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Age and Tenure

4.9yrs

Average Tenure

58.5yo

Average Age

Experienced Board: MTPH's board of directors are considered experienced (4.9 years average tenure).


Insider Trading

Insider Buying: MTPH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUK£13,75003 Oct 19
Stephen Stamp
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares250,000
Max PriceUK£0.055
BuyUK£10,70002 Oct 19
Stephen Stamp
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares200,000
Max PriceUK£0.053

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 215.5%.


Management Team

  • Stephen Stamp (57yo)

    CFO & Director

    • Tenure: 0.2yrs
  • Tim Sparey

    Chief Business Officer

    • Tenure: 0yrs
  • Craig Cook (52yo)

    CEO & Director

    • Tenure: 1.4yrs
    • Compensation: UK£158.77k
  • Justin Barry

    Head of Manufacturing

    • Tenure: 0yrs
  • David Benharris (54yo)

    President of Midatech Pharma US Inc

    • Tenure: 3.8yrs
  • Steve Damment

    Head of Research & Development

    • Tenure: 1.7yrs

Board Members

  • Simon Turton (51yo)

    Senior Independent Non-Executive Director

    • Tenure: 4.9yrs
    • Compensation: UK£30.40k
  • Rolf Stahel (75yo)

    Non-Executive Chairman

    • Tenure: 5.7yrs
    • Compensation: UK£95.00k
  • Stephen Stamp (57yo)

    CFO & Director

    • Tenure: 0.2yrs
  • Dan McCurdy (62yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Simon de Vries (60yo)

    Non-Executive Director

    • Tenure: 15.1yrs
    • Compensation: UK£30.40k
  • Craig Cook (52yo)

    CEO & Director

    • Tenure: 1.4yrs
    • Compensation: UK£158.77k
  • Francesco Stellaci

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • David Male

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Lorraine O'Driscoll

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Soledad Penades

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Midatech Pharma plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Midatech Pharma plc
  • Ticker: MTPH
  • Exchange: AIM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£17.151m
  • Shares outstanding: 469.90m
  • Website: https://www.midatechpharma.com

Number of Employees


Location

  • Midatech Pharma plc
  • Oddfellows House
  • 19 Newport Road
  • Cardiff
  • South Glamorgan
  • CF24 0AA
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MTPHAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPDec 2014
5MPBDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2014
MTPNasdaqCM (Nasdaq Capital Market)SPON ADS EACH REP 20 ORD SHS(R/S)USUSDDec 2015
5MPCBST (Boerse-Stuttgart)SPON ADS EACH REP 20 ORD SHS(R/S)DEEURDec 2015

Biography

Midatech Pharma plc, a biotechnology company, focuses on the research and development of oncology and rare disease products in the United Kingdom. The company is developing MTD201, a long acting dose of Oc ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/10 21:36
End of Day Share Price2019/11/08 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.